Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir’s Zenvia Set Back Two Years, But Path Forward Is Established With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will undertake a new low-dose trial of the involuntary emotional expression disorder treatment to address cardiovascular risks, including QT prolongation.

You may also be interested in...



Avanir's Struggle Was Worth It: Reformulated Zenvia Succeeds In Confirmatory Phase III

Once crushed by an FDA approvable letter for the emotional outburst therapy, the company has battled to stay afloat and now anticipates launching the drug in the second half of 2010.

Avanir's Struggle Was Worth It: Reformulated Zenvia Succeeds In Confirmatory Phase III

Once crushed by an FDA approvable letter for the emotional outburst therapy, the company has battled to stay afloat and now anticipates launching the drug in the second half of 2010.

Avanir's Reformulated Zenvia Succeeds In Confirmatory Phase III

After battling back from a crippling FDA "approvable" letter for Zenvia, its investigational treatment for the sudden and unpredictable emotional outbursts that can accompany neurologic diseases, Avanir is buoyantly predicting a 2010 launch based on positive top-line data from the Phase III confirmatory study it conducted at the agency’s behest.

Related Content

Topics

UsernamePublicRestriction

Register

PS065691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel